199 related articles for article (PubMed ID: 38093196)
41. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
42. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Christensen MC; Munro V
Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
[TBL] [Abstract][Full Text] [Related]
43. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
44. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
[No Abstract] [Full Text] [Related]
45. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
Li Z; Liu S; Wu Q; Li J; Yang Q; Wang X; Peng P; Wang Q; Liu Y; Li M; Hao Y; Xu H; He L; Wang Y; Chen S; Liu T
Int J Neuropsychopharmacol; 2023 Jun; 26(6):373-384. PubMed ID: 37105713
[TBL] [Abstract][Full Text] [Related]
46. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
47. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
48. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
[TBL] [Abstract][Full Text] [Related]
49. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
[TBL] [Abstract][Full Text] [Related]
50. Paroxetine
Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
[TBL] [Abstract][Full Text] [Related]
51. Vortioxetine: A new alternative for the treatment of major depressive disorder.
Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
Cumbo E; Adair M; Åstrom DO; Christensen MC
Front Aging Neurosci; 2022; 14():1037816. PubMed ID: 36698860
[TBL] [Abstract][Full Text] [Related]
53. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
54. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study.
Chokka P; Ge H; Bougie J; Ettrup A; Clerzius G
Ther Adv Psychopharmacol; 2021; 11():20451253211013148. PubMed ID: 34025982
[TBL] [Abstract][Full Text] [Related]
55. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study.
De Berardis D; Fornaro M; Anastasia A; Vellante F; Olivieri L; Rapini G; Serroni N; Orsolini L; Valchera A; Carano A; Tomasetti C; Ventriglio A; Bustini M; Pompili M; Serafini G; Perna G; Iasevoli F; Martinotti G; Di Giannantonio M
Braz J Psychiatry; 2020; 42(3):317-321. PubMed ID: 32159712
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study.
Mattingly G; Brunner E; Chrones L; Lawrence DF; Simonsen K; Ren H
Front Psychiatry; 2022; 13():977560. PubMed ID: 36683990
[TBL] [Abstract][Full Text] [Related]
57. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
[TBL] [Abstract][Full Text] [Related]
58. Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.
Kim H; Baik SY; Kim YW; Lee SH
Neuropsychopharmacol Rep; 2022 Mar; 42(1):21-31. PubMed ID: 34894110
[TBL] [Abstract][Full Text] [Related]
59. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
60. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]